Drug profile · INN
avatrombopag
DOPTELET
avatrombopag (DOPTELET) is a thrombopoietin receptor agonist. Associated with Swedish Orphan Biovitrum Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Blood and blood forming organs (B02) B02BX
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — avatrombopag
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
avatrombopag (DOPTELET) is a thrombopoietin receptor agonist. Associated with Swedish Orphan Biovitrum Pty Ltd.
Key facts
INN avatrombopag
Brand DOPTELET
Mechanism Thrombopoietin receptor agonist
Target Thrombopoietin receptor
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BX
Originator Swedish Orphan Biovitrum Pty Ltd
Mechanism of action
Thrombopoietin receptor agonist
Primary target: Thrombopoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is avatrombopag?
avatrombopag (DOPTELET) is a thrombopoietin receptor agonist. Associated with Swedish Orphan Biovitrum Pty Ltd.
What is the brand name for avatrombopag?
DOPTELET is a marketed brand name for avatrombopag. Check FDA Drugs@FDA for the current US label holder and prescribing information.